

China clears WuXi PharmaTech toxicology facility

20 August 2012 | News | By BioSpectrum Bureau

GLP clearance for WuXi PharmaTech's Suzhou facility



Singapore: Bioscience R&D outsourcing services company WuXi PharmaTech's toxicology facility in Suzhou has received a certificate of Good Laboratory Practice (GLP) from the State Food and Drug Administration (SFDA) of the People's Republic of China.

"WuXi's receipt of this certificate is an acknowledgment that we offer our clients non-clinical laboratory studies that meet national and international GLP quality standards," said Edward Hu, chief operating officer and chief financial officer of WuXi PharmaTech.

Earlier this year, in May, WuXi had received a statement of Good Laboratory Practice from Belgium Scientific Institute of Public Health for the same facility.

Good Laboratory Practice is a quality system concerned with the organizational processes and conditions under which health safety studies are planned, performed, monitored, recorded, archived, and reported.